Failure to phosphorylate AKT in podocytes from mice with early diabetic nephropathy promotes cell death

被引:147
作者
Tejada, T. [1 ]
Catanuto, P. [2 ]
Ijaz, A. [1 ]
Santos, J. V. [1 ]
Xia, X. [2 ]
Sanchez, P. [2 ]
Sanabria, N. [1 ]
Lenz, O. [3 ]
Elliot, S. J. [2 ]
Fornoni, A. [1 ,3 ]
机构
[1] Univ Miami, Miller Sch Med, Diabet Res Inst, Miami, FL 33136 USA
[2] Univ Miami, Miller Sch Med, Dept Surg, Lab Sex & Gender Differences, Miami, FL 33136 USA
[3] Univ Miami, Miller Sch Med, Dept Internal Med, Div Nephrol & Hypertens, Miami, FL 33136 USA
关键词
diabetic nephropathy; AKT; podocytes; insulin signaling; cell death;
D O I
10.1038/ki.2008.109
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Loss of podocytes by apoptosis characterizes the early stages of diabetic nephropathy. To examine its mechanism we studied glomeruli and podocytes isolated from db/db mice with early diabetic nephropathy and albuminuria. Phosphorylation of AKT (protein kinase B, a key survival protein) was found to be lower in the glomeruli of 12 week old db/db compared to db/+ mice. In vitro, insulin phosphorylated AKT solely in podocytes from db/+ mice. Serum deprivation and exposure to tumor necrosis factor-alpha significantly compromised cell viability in podocytes from db/ db but not from db/+ mice, and this was associated with a significant decrease in AKT phosphorylation. Inhibition of AKT was necessary to achieve the same degree of cell death in db/+ podocytes. Our study shows that podocyte inability to respond to insulin and susceptibility to cell death may partially account for the decreased podocyte number seen in early diabetic nephropathy.
引用
收藏
页码:1385 / 1393
页数:9
相关论文
共 44 条
[1]  
Breyer MD, 2005, J AM SOC NEPHROL, V16, P27, DOI [10.1681/ASN.2004080648, 10.1681/ASN.2009070721]
[2]   Statins prevent oxidized LDL-induced injury of glomerular podocytes by activating the phosphatidylinositol 3-kinase/AKT-signaling pathway [J].
Bussolati, B ;
Deregibus, MC ;
Fonsato, V ;
Doublier, S ;
Spatola, T ;
Procida, S ;
Di Carlo, F ;
Camussi, G .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2005, 16 (07) :1936-1947
[3]   Phosphoinositide 3-kinase is required for high glucose-induced hypertrophy and p21WAF1 expression in LLC-PK1 cells [J].
Chuang, T-D ;
Guh, J-Y ;
Chiou, S-J ;
Chen, H-C ;
Huang, J-S ;
Yang, Y-L ;
Chuang, L-Y .
KIDNEY INTERNATIONAL, 2007, 71 (09) :867-874
[4]   Nephrin is critical for the action of insulin on human glomerular podocytes [J].
Coward, Richard J. M. ;
Welsh, Gavin I. ;
Koziell, Ania ;
Hussain, Sagair ;
Lennon, Rachel ;
Ni, Lan ;
Tavare, Jeremy M. ;
Mathieson, Peter W. ;
Saleem, Moin A. .
DIABETES, 2007, 56 (04) :1127-1135
[5]   The human glomerular podocyte is a novel target for insulin action [J].
Coward, RJM ;
Welsh, GI ;
Yang, J ;
Tasman, C ;
Lennon, R ;
Koziell, A ;
Satchell, S ;
Holman, GD ;
Kerjaschki, D ;
Tavaré, JM ;
Mathieson, PW ;
Saleem, MA .
DIABETES, 2005, 54 (11) :3095-3102
[6]   Is podocyte injury relevant in diabetic nephropathy? Studies in patients with type 2 diabetes [J].
Dalla Vestra, M ;
Masiero, A ;
Roiter, AM ;
Saller, A ;
Crepaldi, G ;
Fioretto, P .
DIABETES, 2003, 52 (04) :1031-1035
[7]   Transformation by the simian virus 40 T antigen is regulated by IGF-I receptor and IRS-1 signaling [J].
DeAngelis, T ;
Chen, J ;
Wu, A ;
Prisco, M ;
Baserga, R .
ONCOGENE, 2006, 25 (01) :32-42
[8]   Activation of renal signaling pathways in db/db mice with type 2 diabetes [J].
Feliers, D ;
Duraisamy, S ;
Faulkner, JL ;
Duch, J ;
Lee, AV ;
Abboud, HE ;
Choudhury, GG ;
Kasinath, BS .
KIDNEY INTERNATIONAL, 2001, 60 (02) :495-504
[9]   Low insulin-like growth factor binding protein-2 expression is responsible for increased insulin receptor substrate-1 phosphorylation in mesangial cells from mice susceptible to glomerulosclerosis [J].
Fornoni, A ;
Rosenzweig, SA ;
Lenz, O ;
Rivera, A ;
Striker, GE ;
Elliot, SJ .
ENDOCRINOLOGY, 2006, 147 (07) :3547-3554
[10]   Reversibility of glucose-induced changes in mesangial cell extracellular matrix depends on the genetic background [J].
Fornoni, A ;
Striker, LJ ;
Zheng, F ;
Striker, GE .
DIABETES, 2002, 51 (02) :499-505